LeMaitre Vascular (LMAT) is back in focus after recent share price moves, with the stock last closing at US$93.95. Investors are weighing this level against the company’s fundamentals and recent return profile.

Recent momentum in LeMaitre Vascular has been mixed, with a 1-day share price return of 1.89% and a year to date share price return of 17.19%, while the 1-year total shareholder return stands at 15.94% and the 5-year total shareholder return at 55.47%.

If this kind of sustained performance has you thinking about what else might be worth watching, it could be a good time to scan the market using our screener for 40 healthcare AI stocks

With LeMaitre Vascular posting a 15.94% 1-year total shareholder return and trading at US$93.95, along with a sizeable gap to the US$118.75 analyst price target, the key question is simple: is there real upside left, or is the market already pricing in future growth?

Most Popular Narrative: 20.9% Undervalued

LeMaitre Vascular’s most followed narrative points to a fair value of $118.75, well above the recent $93.95 close. This frames the current analyst debate around upside potential and execution risk.

Robust growth in international markets, particularly Europe and emerging regions, is being driven by new product launches (such as Artegraft and RestoreFlow) and ongoing regulatory approvals in countries like Germany, Ireland, Canada, Korea, and Singapore, establishing significant new revenue streams and underpinning future revenue growth.

Want to understand why this narrative supports a premium earnings multiple and higher fair value? The crux is a specific mix of revenue growth, margin assumptions, and future valuation levels that go well beyond today’s headline numbers.

Result: Fair Value of $118.75 (UNDERVALUED)

However, investors in LeMaitre Vascular also need to watch for slower international approvals or pressure on pricing, either of which could challenge the current growth focused narrative.

Another View On LeMaitre Vascular’s Valuation

The analyst narrative points to LeMaitre Vascular being 20.9% undervalued at US$93.95 based on future earnings and a higher P/E in 2029. Yet our DCF model, which focuses on projected cash flows, indicates the stock is expensive at this price.

Our DCF model estimates a future cash flow value of US$67.84, so at US$93.95 LeMaitre Vascular trades well above that level. For readers, the tension between a higher earnings based fair value and a lower cash flow based value raises a simple question: which framework do you trust more for this kind of business?

Next Steps

If the mixed signals around LeMaitre Vascular have you on the fence, now is a good time to review the numbers and sentiment yourself, then weigh up the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond LeMaitre Vascular?

If LeMaitre Vascular has sharpened your focus on quality, do not stop here. Use the Simply Wall Street Screener to uncover more focused investment ideas today.

• Target potential bargains by scanning for companies that combine quality fundamentals with attractive pricing using the 45 high quality undervalued stocks.
• Prioritize financial strength by zeroing in on companies selected through the solid balance sheet and fundamentals stocks screener (48 results).
• Spot under followed opportunities by reviewing the screener containing 19 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.